This post was originally published on this site
The London-listed drugmaker generated $10.98 billion total revenue for the three months ended Sep. 30 on a constant-currency basis, while core earnings came in at $1.67 cents per share.
Analysts on average were expecting profit of $1.52 cents per share on revenue of around $10.73 billion, based on Refinitiv data.
